The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
Academician Workstation, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
PLoS One. 2022 Feb 8;17(2):e0263581. doi: 10.1371/journal.pone.0263581. eCollection 2022.
Threatened miscarriages is a common complication of first-trimester pregnancy. Due to the beneficial effects, there are increasing clinical studies on Yunkang oral liquid(YKOL). However, the efficacy and safety of YKOL are still unknown. The aim of this systematic review was to assess the efficacy and safety of YKOL in the treatment of threatened miscarriage during the first-trimester pregnancy (TMFP).
This protocol will be prepared according to the preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) statement. The systematic review will include all randomized controlled trials (RCTs) studies published until April 2021. Electronic sources including CNKI, WF, VIP, CBM, MEDLINE(PubMed), Embase, Cochrane Library, and Web of Science will be searched for potentially eligible studies. The international clinical trial registration platform and the Chinese clinical trial registration platform of controlled trials will be searched from their inception until April 1st, 2021. According to the inclusion and exclusion criteria, screening literature, extraction data will be conducted by two researchers independently. Statistical analysis will use RevMan 5.3.5 software. The strength of evidence from the studies will be evaluated with the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) methods.
This study will provide evidence for YKOL combined with conventional therapy for TMFP.
The efficacy and safety of YKOL combined with conventional therapy for TMFP will be assessed.
INPLASY202140105 (https://www.doi.org/10.37766/inplasy2021.4.0105).
早期妊娠的先兆流产是一种常见的并发症。由于其有益的作用，越来越多的临床研究关注于孕康口服液（YKOL）。然而，YKOL 的疗效和安全性仍不清楚。本系统评价的目的是评估 YKOL 在治疗早期妊娠先兆流产（TMFP）中的疗效和安全性。
本方案将按照系统评价和荟萃分析优先报告项目（PRISMA-P）声明进行制定。系统评价将包括截至 2021 年 4 月发表的所有随机对照试验（RCT）研究。电子资源包括中国知网（CNKI）、万方（WF）、维普（VIP）、中国生物医学文献数据库（CBM）、MEDLINE（PubMed）、Embase、考克兰图书馆（Cochrane Library）和 Web of Science 将被搜索以寻找潜在的合格研究。国际临床试验注册平台和中国临床试验注册平台的对照试验将从成立到 2021 年 4 月 1 日进行搜索。根据纳入和排除标准，两名研究人员将独立筛选文献并提取数据。统计分析将使用 RevMan 5.3.5 软件进行。研究证据的强度将使用推荐评估、制定与评价（GRADE）方法进行评估。
本研究将为 YKOL 联合常规疗法治疗 TMFP 提供证据。
将评估 YKOL 联合常规疗法治疗 TMFP 的疗效和安全性。
INPLASY202140105（https://www.doi.org/10.37766/inplasy2021.4.0105）。
